The presence of TERT promoter mutations showed a superior specificity for tumour clinical aggressiveness than the methylation of TERT promoter, as only 3.4% (2/58) against 10.9% (6/55) of disease‐free tumours were positive for TERT promoter mutations and promoter methylation, respectively (Figure S3A,B). This evidence concerns the gene TERT and neoplasm.